Lyon

• GASTRICHIP TRIAL. D2 resection and HIPEC (Hyperthermic IntraPeritoneal Chemoperfusion) in locally advanced gastric carcinoma. Ended
  2024-516358-23-00 5 2013-06-24 Gastric adenocarcinoma
• A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolera … Ended
  2024-510784-36-00 9 2009-04-27 Children and Adolescents with Newly Diagnosed Chronic Phase CML or wit
• A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastro … Ended
  2022-502087-21-00 7 Gastrointestinal Stromal Tumors (GIST)
• A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors Ended
  2022-502622-40-00 1 Advanced Solid Tumors
• PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc … Ended
  2023-503807-27-00 4 Biliary tract carcinoma
• A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with … Ended
  2023-506240-16-00 9 Acute Myeloid Leukemia (AML)
• A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic … Ended
  2023-507344-36-01 4 Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Sq
• A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers Ended
  2023-507674-41-00 1 Advanced high-grade serous ovarian cancer (OC)
• ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati … Ended
  2023-509227-41-00 4 Low risk of disease recurrence, defined by the following criteria: - A
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI) Ended
  2024-511857-23-00 4 cancerology
• Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative settin … Ended
  2024-514078-29-00 4 gastric and gastro-oesophageal junction adenocarcinomas
• A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons … Ended
  2024-515393-27-00 4 Nonsquamous non-small cell lung cancer
• Trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer Ended
  2024-516558-24-00 4 Pancreatic (PAAD)
• Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre … Ended
  2024-516724-33-00 9 Advanced/metastatic gynecological cancer overexpressing FGFR2b
• DCC-3084 monotherapy in patients with solid tumors Ended
  2024-517829-12-00 7 Solid tumors driven by the MAPK Pathway
• First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors Ended
  2024-517984-21-00 1 Advanced Solid Tumors
• PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended
  2024-519258-35-00 4 stomach cancer

Showing 865–882 of 882 trials